Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs TG Therapeutics Inc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.62 (market cap $1.45B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 5.6× YieldMax NVDA Option Income Strategy ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax NVDA Option Income Strategy ETF for 43 Days and TG Therapeutics Inc for 16 Days on average.
| NVDY | TGTX | |
|---|---|---|
Market Cap | $1.45B | $8.16B |
Volume | 1,943,739 | 1,735,121 |
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $59.06 |
52-Week Low | $11.58 | $26.94 |
Typical Hold Time | 43 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY trades at $12.57, down 3.38% with a bearish technical outlook. The ETF generates weekly dividends but faces structural limitations on upside participation. Recent analyst coverage highlights concerns about declining volatility reducing option income potential. Technical indicators show bearish momentum with support at $12 and resistance at $13.
The outlook remains cautious as NVDY's high distribution yield comes at the cost of NAV erosion. While weekly dividends provide income, the fund's capped upside during NVIDIA rallies and dependence on volatility create long-term performance challenges. Investors seeking pure NVIDIA exposure may find direct ownership more attractive.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
